| Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial Y Shi, H Su, Y Song, W Jiang, X Sun, W Qian, W Zhang, Y Gao, Z Jin, ... The Lancet Haematology 6 (1), e12-e19, 2019 | 218 | 2019 |
| Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China Y Shi, B Jia, W Xu, W Li, T Liu, P Liu, W Zhao, H Zhang, X Sun, H Yang, ... Journal of hematology & oncology 10, 1-5, 2017 | 185 | 2017 |
| CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies H Qin, Z Dong, X Wang, WA Cheng, F Wen, W Xue, H Sun, M Walter, ... Science translational medicine 11 (511), eaaw9414, 2019 | 77 | 2019 |
| The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia Q Liu, H Ma, X Sun, B Liu, Y Xiao, S Pan, H Zhou, W Dong, L Jia Journal of Experimental & Clinical Cancer Research 38, 1-15, 2019 | 56 | 2019 |
| Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure S Hu, Y Song, X Sun, L Su, W Zhang, J Jia, O Bai, S Yang, R Liang, X Li, ... Cancer Science 109 (12), 3943-3952, 2018 | 38 | 2018 |
| Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab Y Shi, H Su, Y Song, W Jiang, X Sun, W Qian, W Zhang, Y Gao, Z Jin, ... EBioMedicine 54, 2020 | 28 | 2020 |
| Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: a multicenter phase II trial Y Wang, M Zhang, W Song, Q Cai, L Zhang, X Sun, L Zou, H Zhang, ... American Journal of Hematology 97 (5), 623-629, 2022 | 18 | 2022 |
| Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway K Liu, J Song, Y Yan, K Zou, Y Che, B Wang, Z Li, W Yu, W Guo, L Zou, ... Translational Oncology 14 (1), 100876, 2021 | 18 | 2021 |
| A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL). Y Song, K Zhou, C Jin, Z Qian, M Hou, L Fan, F Li, K Ding, H Zhou, X Li, ... Journal of Clinical Oncology 39 (15_suppl), 7529-7529, 2021 | 14 | 2021 |
| ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic … GS Nowakowski, J Zhu, Q Zhang, J Brody, X Sun, J Maly, Y Song, S Rizvi, ... Future Oncology 16 (15), 991-999, 2020 | 12 | 2020 |
| The oral PI3Kδ inhibitor Linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial T Wang, X Sun, L Qiu, H Su, J Cao, Z Li, Y Song, L Zhang, D Li, H Wu, ... Clinical Cancer Research 29 (8), 1440-1449, 2023 | 11 | 2023 |
| Bufalin: A systematic review of research hotspots and antitumor mechanisms by text mining and bioinformatics X Zhang, X Zhao, K Liu, Y Che, X Qiu, Y Qu, X Sun, J Song The American Journal of Chinese Medicine 48 (07), 1633-1650, 2020 | 10 | 2020 |
| Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. H Su, Y Song, W Jiang, X Sun, W Qian, W Zhang, Y Gao, Z Jin, J Zhou, ... Journal of Clinical Oncology 38 (15_suppl), 8034-8034, 2020 | 10 | 2020 |
| Prospective and prognostic factors for hepatic metastasis of gastric carcinoma: A retrospective analysis JC Song, XL Ding, Y Zhang, X Zhang, XH Sun Journal of Cancer Research and Therapeutics 15 (2), 298-304, 2019 | 10 | 2019 |
| The prognosis factors research on the 172 non-hodgkin lymphoma cases JN Jiang, XH Sun Biomedical Research 27 (2), 336-44, 2016 | 9 | 2016 |
| Primary sternum diffuse large B‑cell lymphoma: A case report and review of the literature Corrigendum in/10.3892/ol. 2021.12453 MY Tong, X Zhang, Z Yu, XH Sun, S Li, Y Zhang Oncology letters 9 (6), 2623-2628, 2015 | 9 | 2015 |
| The clinical evaluation of Iressa first-line treatment of senium advanced-stage non-small cell lung cancer X Sun, Y Zhang, X Zhang, J Yu, Y Li, X Yang, Z Dai, M Li The Chinese-German Journal of Clinical Oncology 7, 203-206, 2008 | 9 | 2008 |
| Penpulimab for relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, pivotal phase I/II trial (AK105-201) Y Song, K Zhou, C Jin, Z Qian, M Hou, L Fan, F Li, K Ding, H Zhou, X Li, ... Frontiers in Oncology 12, 925236, 2022 | 8 | 2022 |
| Critical involvement of the α (1, 2)-fucosyltransferase in multidrug resistance of human chronic myeloid leukemia Y Che, X Ren, L Xu, X Ding, X Zhang, X Sun Oncology Reports 35 (5), 3025-3033, 2016 | 7 | 2016 |
| An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy Y Lu, J Yu, W Gong, L Su, X Sun, O Bai, H Zhou, X Guan, T Zhang, L Li, ... Frontiers in Oncology 11, 708784, 2021 | 6 | 2021 |
